Back to Interventions

Substance / Medication

Bupropion

SNOMED 387564004 UMLS C0085208

Overview

Active Ingredient

bupropion

RxNorm CUI

42347

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Depressive disorder

Attention deficit hyperactivity disorder

Harmful pattern of use of tobacco

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Calcidiol+ercalcidiol

LOINC 14635-7

secondary

LOINC 2132-9

secondary

LOINC 3016-3

secondary

Clinical Trials

133 trials linked to this intervention

133

Total Trials

21

Recruiting

60

With Results

Recent Trials

Continuation Electroconvulsive Therapy Vs Medication to Prevent Relapses in Patients With Major Depressive Disorder

NCT00000375Phase 4Completed

Antidepressant Treatment of Melancholia in Late Life

NCT00000378Phase 4Completed110 enrolled

Bupropion and Weight Control for Smoking Cessation - 1

NCT00006170Phase 4Completed349 enrolled

Optimizing Electroconvulsive Therapy for Depression

NCT00045916Phase 4Completed340 enrolled

Ethnic Variations in Antidepressant Response

NCT00047671Phase 4Completed400 enrolled

View all 133 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Efficacy and safety of dextromethorphan-bupropion combination (AXS-05) in the treatment of depression: A systematic review and network meta-analysis.

Ashwin J V, Shahi Mohit Kumar, Singh Astha et al. · Indian J Pharmacol · 2025

PMID: 40686359Meta-AnalysisFull text (PMC)

Efficacy of naltrexone and bupropion combination in patients with binge eating disorder: a systematic review and meta-analysis.

Roudbaraki Seyedeh Narjes, Salimi Mostafa, Esmailpour Sina et al. · Eat Weight Disord · 2025

PMID: 41003943Meta-AnalysisFull text (PMC)

Efficacy and Tolerability of Bupropion in Major Depressive Disorder with Comorbid Anxiety Symptoms: A Systematic Review.

Pinzi Mario, Cuomo Alessandro, Koukouna Despoina et al. · Int J Mol Sci · 2025

PMID: 41465198Meta-AnalysisFull text (PMC)

The weight reducing effects of naltrexone-bupropion among obese psychiatric and non-psychiatric patients: a systematic review.

Alim Ur Rahman Hafsah, Fahim Muhammad Ahmed Ali, Naeem Unaiza et al. · Psychopharmacology (Berl) · 2025

PMID: 40853467Meta-Analysis

Naltrexone-bupropion for the treatment of binge eating disorder: a systematic review and meta-analysis.

Marçal Jordana Belgamasco Cavalcanti, Sobral Milene Vitória Sampaio, Ellwanger Maurício Prätzel et al. · Braz J Psychiatry · 2025

PMID: 41022489Meta-AnalysisFull text (PMC)

Changes in lipid profile and glucose metabolism following administration of bupropion alone or in combination with naltrexone: A systematic review and meta-regression analysis.

Hu Yi, Velu Periyannan, Rohani Pejman et al. · Eur J Clin Invest · 2024

PMID: 37929909Meta-Analysis

The effects of bupropion alone and combined with naltrexone on blood pressure and CRP concentration: A systematic review and meta-regression analysis of randomized controlled trials.

Jiang Qidong, Velu Periyannan, Sohouli Mohammad Hassan et al. · Eur J Clin Invest · 2024

PMID: 37924302Meta-Analysis

Efficacy and safety of aripiprazole or bupropion augmentation and switching in patients with treatment-resistant depression or major depressive disorder: A systematic review and meta-analysis of randomized controlled trials.

Ji Mengjia, Feng Junfei, Liu Guirong · PLoS One · 2024

PMID: 38669232Meta-AnalysisFull text (PMC)

Bupropion for treatment of amphetamine-type stimulant use disorder: A systematic review and meta-analysis of placebo-controlled randomized clinical trials.

Bakouni Hamzah, Sharafi Heidar, Bahremand Arash et al. · Drug Alcohol Depend · 2023

PMID: 37979478Meta-Analysis

Dextromethorphan-Bupropion for the Treatment of Depression: A Systematic Review of Efficacy and Safety in Clinical Trials.

Akbar Dania, Rhee Taeho Greg, Ceban Felicia et al. · CNS Drugs · 2023

PMID: 37792265Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Specialists

Providers who commonly manage this intervention

Internal Medicine Physician

Internal Medicine

NUCC 207R00000X

Psychiatry Physician

Psychiatry & Neurology — Psychiatry

NUCC 2084P0800X

Find a Provider

Health Goals

Goals connected through associated conditions

Support Mental Wellness

Quick Facts

Type: Substance / Medication
Fully Specified Name: Bupropion (substance)
SNOMED CT: 387564004
UMLS CUI: C0085208
RxNorm CUI: 42347

Clinical Data

This intervention maps to 9 entities in the Ltrl knowledge graph.

3

Conditions

3

Biomarkers

2

Specialists

0

Symptoms

133

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.